Cancers, Vol. 16, Pages 1707: Utility of Clinical Next Generation Sequencing Tests in KIT/PDGFRA/SDH Wild-Type Gastrointestinal Stromal Tumors

Conclusions: Triple-negative GISTs comprise a diverse cohort with different driver mutations. Compared to KIT/PDGFRA-mutant GIST, limited benefit was observed with imatinib in triple-negative GIST. In depth molecular profiling can be helpful in identifying driver mutations and guiding therapy.

Source: Cancers - April 27, 2024 Category: Cancer & Oncology Authors: Ryan A. Denu Cissimol P. Joseph Elizabeth S. Urquiola Precious S. Byrd Richard K. Yang Ravin Ratan Maria Alejandra Zarzour Anthony P. Conley Dejka M. Araujo Vinod Ravi Elise F. Nassif Haddad Michael S. Nakazawa Shreyaskumar Patel Wei-Lien Wang Alexander J Tags: Article Source Type: research